NASDAQ:RYTM - Rhythm Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$30.19 -0.09 (-0.30 %)
(As of 05/27/2018 04:00 PM ET)
Previous Close$30.19
Today's Range$29.70 - $30.93
52-Week Range$16.80 - $33.81
Volume196,738 shs
Average Volume156,402 shs
Market Capitalization$831.13 million
P/E Ratio-10.67
Dividend YieldN/A
BetaN/A

About Rhythm Pharmaceuticals (NASDAQ:RYTM)

Rhythm Pharmaceuticals logoRhythm Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. Its peptide candidates include Setmelanotide, a melanocortin-4 receptor agonist, which is in Phase III clinical trial to treat POMC and leptin receptor deficiency obesity; and Phase II clinical trial for Bardet-Biedl and Alström syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. Rhythm Pharmaceuticals, Inc. is a subsidiary of Motus Therapeutics, Inc.

Receive RYTM News and Ratings via Email

Sign-up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RYTM
CUSIPN/A
Phone857-264-4280

Debt

Debt-to-Equity RatioN/A
Current Ratio24.85
Quick Ratio24.85

Price-To-Earnings

Trailing P/E Ratio-10.67
Forward P/E Ratio-16.41
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.85 per share
Price / Book6.22

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees26
Outstanding Shares27,530,000

Rhythm Pharmaceuticals (NASDAQ:RYTM) Frequently Asked Questions

What is Rhythm Pharmaceuticals' stock symbol?

Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."

How were Rhythm Pharmaceuticals' earnings last quarter?

Rhythm Pharmaceuticals (NASDAQ:RYTM) released its earnings results on Monday, May, 14th. The company reported ($0.60) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.45) by $0.15. View Rhythm Pharmaceuticals' Earnings History.

What price target have analysts set for RYTM?

4 brokerages have issued 12-month price objectives for Rhythm Pharmaceuticals' shares. Their forecasts range from $23.00 to $40.00. On average, they expect Rhythm Pharmaceuticals' stock price to reach $31.25 in the next year. View Analyst Ratings for Rhythm Pharmaceuticals.

What are Wall Street analysts saying about Rhythm Pharmaceuticals stock?

Here are some recent quotes from research analysts about Rhythm Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide, a potent, first-in-class melanocortin-4 receptor or MC4R, agonist for the treatment of rare genetic disorders of obesity. Rhythm Pharmaceuticals, Inc. is based in Boston, MA. " (5/23/2018)
  • 2. Needham & Company LLC analysts commented, "We hosted a series of mtgs with mgmt and investors last wk. Enrollment in setmelanotide Phase 3 trial in POMC patients is nearing completion. Mgmt did not disclose current enrollment figure, but did reiterate guidance for completion in 1H18. Phase 3 trial in LepR patients has been initiated. Mgmt still expects to complete enrollment of this latter trial by YE18, noting help from an overlap in sites w/ POMC trial and higher prevalence. A mtg w/ FDA to discuss Bardet-Biedl Phase 3 design is scheduled. Trial likely to be somewhat larger, but it is not yet clear whether a placebo arm will be needed. We expect initial data from Phase 2 testing in Alstrom, Epigenetic POMC, and possibly Heterozygous POMC patients in 1H18. Mgmt did not guide on timing for an update on Bardet-Biedl Phase 2 trial, but did convey a bias towards expectations for a more profound impact on weight loss w/ longer duration treatment. Reiterate BUY. We believe Phase 2 POMC and LepR data are compelling and have high conviction around positive Phase 3 outcomes in 2019. We believe stock has room for upside around positive Phase 2 trial updates in 1H19, which would expand peak sales potential." (2/26/2018)
  • 3. Cowen Inc analysts commented, "Rhythm released Q3 financials this morning, following the presentation of promising." (11/14/2017)

Who are some of Rhythm Pharmaceuticals' key competitors?

Who are Rhythm Pharmaceuticals' key executives?

Rhythm Pharmaceuticals' management team includes the folowing people:
  • Dr. Keith Michael Gottesdiener, Exec. Director (Age 64)
  • Dr. Fred T. Fiedorek M.D., Chief Medical Officer (Age 63)
  • Mr. Hunter C. Smith, CFO & Treasurer (Age 49)
  • Mr. Leonardus H.T. van der Ploeg Ph.D., Chief Scientific Officer (Age 63)
  • Ms. Nithya Desikan, Chief Commercial Officer (Age 39)

When did Rhythm Pharmaceuticals IPO?

(RYTM) raised $100 million in an initial public offering on Thursday, October 5th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager.

When did the company's lock-up period expire?

Rhythm Pharmaceuticals' lock-up period expired on Tuesday, April 3rd. Rhythm Pharmaceuticals had issued 7,050,000 shares in its initial public offering on October 5th. The total size of the offering was $119,850,000 based on an initial share price of $17.00. Since the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

Has Rhythm Pharmaceuticals been receiving favorable news coverage?

News coverage about RYTM stock has trended somewhat positive on Sunday, according to Accern Sentiment. The research group ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Rhythm Pharmaceuticals earned a daily sentiment score of 0.08 on Accern's scale. They also assigned media headlines about the company an impact score of 46.31 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are Rhythm Pharmaceuticals' major shareholders?

Rhythm Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (1.40%), Foresite Capital Management IV LLC (0.73%), Point72 Asset Management L.P. (0.65%), JPMorgan Chase & Co. (0.57%), Franklin Resources Inc. (0.39%) and Northern Trust Corp (0.33%). Company insiders that own Rhythm Pharmaceuticals stock include Bros Advisors Lp Baker, David P Meeker, James E Flynn, Orbimed Advisors Llc and SA Ipsen. View Institutional Ownership Trends for Rhythm Pharmaceuticals.

Which institutional investors are selling Rhythm Pharmaceuticals stock?

RYTM stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC and Franklin Resources Inc.. View Insider Buying and Selling for Rhythm Pharmaceuticals.

Which institutional investors are buying Rhythm Pharmaceuticals stock?

RYTM stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Russell Investments Group Ltd., JPMorgan Chase & Co., Alps Advisors Inc., BlackRock Inc., Foresite Capital Management IV LLC and Northern Trust Corp. Company insiders that have bought Rhythm Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, David P Meeker, James E Flynn and SA Ipsen. View Insider Buying and Selling for Rhythm Pharmaceuticals.

How do I buy shares of Rhythm Pharmaceuticals?

Shares of RYTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Rhythm Pharmaceuticals' stock price today?

One share of RYTM stock can currently be purchased for approximately $30.19.

How big of a company is Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals has a market capitalization of $831.13 million. The company earns $-33,700,000.00 in net income (profit) each year or ($2.83) on an earnings per share basis. Rhythm Pharmaceuticals employs 26 workers across the globe.

How can I contact Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals' mailing address is 500 BOYLSTON STREET 11TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-264-4280 or via email at [email protected]


MarketBeat Community Rating for Rhythm Pharmaceuticals (RYTM)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  72 (Vote Outperform)
Underperform Votes:  73 (Vote Underperform)
Total Votes:  145
MarketBeat's community ratings are surveys of what our community members think about Rhythm Pharmaceuticals and other stocks. Vote "Outperform" if you believe RYTM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RYTM will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Rhythm Pharmaceuticals in the last 12 months. Their average twelve-month price target is $31.25, suggesting that the stock has a possible upside of 3.51%. The high price target for RYTM is $40.00 and the low price target for RYTM is $23.00. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.752.752.75
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $31.25$31.25$31.25$31.25
Price Target Upside: 3.51% upside13.18% upside13.18% upside22.74% upside

Rhythm Pharmaceuticals (NASDAQ:RYTM) Consensus Price Target History

Price Target History for Rhythm Pharmaceuticals (NASDAQ:RYTM)

Rhythm Pharmaceuticals (NASDAQ:RYTM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/26/2018Needham & Company LLCReiterated RatingBuy$32.00HighView Rating Details
11/14/2017CowenReiterated RatingBuy$40.00N/AView Rating Details
10/30/2017Morgan StanleyInitiated CoverageEqual Weight$23.00N/AView Rating Details
10/30/2017Bank of AmericaInitiated CoverageBuy$30.00N/AView Rating Details
(Data available from 5/27/2016 forward)

Earnings

Rhythm Pharmaceuticals (NASDAQ:RYTM) Earnings History and Estimates Chart

Earnings by Quarter for Rhythm Pharmaceuticals (NASDAQ:RYTM)

Rhythm Pharmaceuticals (NASDAQ:RYTM) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.84 EPS
Next Year EPS Consensus Estimate: $-2.35 EPS

Rhythm Pharmaceuticals (NASDAQ RYTM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/14/20183/31/2018($0.45)($0.60)ViewN/AView Earnings Details
3/12/2018Q4 2017($0.55)($0.41)ViewN/AView Earnings Details
11/14/2017Q3 2017($0.3970)($1.78)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Rhythm Pharmaceuticals (NASDAQ:RYTM) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Rhythm Pharmaceuticals (NASDAQ RYTM) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 88.24%
Insider Trading History for Rhythm Pharmaceuticals (NASDAQ:RYTM)
Institutional Ownership by Quarter for Rhythm Pharmaceuticals (NASDAQ:RYTM)

Rhythm Pharmaceuticals (NASDAQ RYTM) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/21/2018Orbimed Advisors LlcMajor ShareholderSell131,636$30.88$4,064,919.68View SEC Filing  
10/10/2017David P MeekerDirectorBuy25,000$17.00$425,000.00View SEC Filing  
10/10/2017James E FlynnInsiderBuy355,000$17.00$6,035,000.00View SEC Filing  
10/10/2017S.A. IpsenMajor ShareholderBuy20,000$17.00$340,000.00View SEC Filing  
10/5/2017Bros. Advisors Lp BakerInsiderBuy885,000$17.00$15,045,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Rhythm Pharmaceuticals (NASDAQ RYTM) News Headlines

Source:
DateHeadline
 Analysts Expect Rhythm Pharmaceuticals (RYTM) Will Post Earnings of -$0.41 Per Share Analysts Expect Rhythm Pharmaceuticals (RYTM) Will Post Earnings of -$0.41 Per Share
www.americanbankingnews.com - May 27 at 7:32 AM
Rhythm Pharmaceuticals (RYTM) Major Shareholder Sells $4,064,919.68 in StockRhythm Pharmaceuticals (RYTM) Major Shareholder Sells $4,064,919.68 in Stock
www.americanbankingnews.com - May 21 at 10:10 PM
Rhythm Pharmaceuticals (RYTM) Receives Consensus Rating of "Buy" from AnalystsRhythm Pharmaceuticals (RYTM) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 19 at 3:22 AM
Dodos Singer Meric Long Tells the Story Behind Every Song on His Grief-Inspired New Solo Album, Bartons DenDodos Singer Meric Long Tells the Story Behind Every Song on His Grief-Inspired New Solo Album, 'Barton's Den'
www.msn.com - May 16 at 4:03 PM
Rhythm Pharmaceuticals (RYTM) Upgraded at Zacks Investment ResearchRhythm Pharmaceuticals (RYTM) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 16 at 3:01 PM
Rhythm Pharmaceuticals (RYTM) Announces Quarterly  Earnings ResultsRhythm Pharmaceuticals (RYTM) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 15 at 7:34 AM
Rhythm Pharmaceuticals (RYTM) Misses Q1 EPS by 15cRhythm Pharmaceuticals (RYTM) Misses Q1 EPS by 15c
www.streetinsider.com - May 14 at 10:59 AM
Rhythm Pharmaceuticals Reports First Quarter 2018 Financial ResultsRhythm Pharmaceuticals Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 14 at 10:59 AM
Rhythm Pharmaceuticals Announces Nature Medicine Publication of Longer-Term Data from Phase 2 StudyRhythm Pharmaceuticals Announces Nature Medicine Publication of Longer-Term Data from Phase 2 Study
www.nasdaq.com - May 10 at 10:12 AM
 Brokerages Expect Rhythm Pharmaceuticals (RYTM) to Announce -$0.45 Earnings Per Share Brokerages Expect Rhythm Pharmaceuticals (RYTM) to Announce -$0.45 Earnings Per Share
www.americanbankingnews.com - May 10 at 5:24 AM
Rhythm Pharmaceuticals to Present at the Bank of America Merrill Lynch 2018 Health Care ConferenceRhythm Pharmaceuticals to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
finance.yahoo.com - May 9 at 4:06 PM
Rhythm Pharmaceuticals Announces Nature Medicine Publication of Longer-Term Data from Phase 2 Study of Setmelanotide for Treatment of LEPR Deficiency ObesityRhythm Pharmaceuticals Announces Nature Medicine Publication of Longer-Term Data from Phase 2 Study of Setmelanotide for Treatment of LEPR Deficiency Obesity
finance.yahoo.com - May 9 at 4:06 PM
Rhythm Pharmaceuticals (RYTM) Upgraded at BidaskClubRhythm Pharmaceuticals (RYTM) Upgraded at BidaskClub
www.americanbankingnews.com - May 4 at 1:50 PM
Rhythm Pharmaceuticals (RYTM) Raised to "Hold" at ValuEngineRhythm Pharmaceuticals (RYTM) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - May 2 at 6:30 PM
Rhythm Pharmaceuticals (RYTM) Receives Average Recommendation of "Hold" from AnalystsRhythm Pharmaceuticals (RYTM) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 24 at 11:12 AM
Rhythm Pharmaceuticals (RYTM) Rating Lowered to Sell at Zacks Investment ResearchRhythm Pharmaceuticals (RYTM) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - April 24 at 11:02 AM
-$0.45 EPS Expected for Rhythm Pharmaceuticals (RYTM) This Quarter-$0.45 EPS Expected for Rhythm Pharmaceuticals (RYTM) This Quarter
www.americanbankingnews.com - April 22 at 9:10 PM
NeuroVive Presents NVP025 Mitochondrial Myopathy Project Progress at Mitochondrial Medicine ConferenceNeuroVive Presents NVP025 Mitochondrial Myopathy Project Progress at Mitochondrial Medicine Conference
www.prnewswire.com - April 20 at 10:11 AM
Consolidated Research: 2018 Summary Expectations for Ctrip.com International, JA Solar Holdings, CoConsolidated Research: 2018 Summary Expectations for Ctrip.com International, JA Solar Holdings, Co
www.nasdaq.com - April 20 at 10:11 AM
Rhythm Pharmaceuticals (RYTM) Short Interest Down 27.3% in MarchRhythm Pharmaceuticals (RYTM) Short Interest Down 27.3% in March
www.americanbankingnews.com - April 15 at 2:01 AM
Rhythm Pharmaceuticals Diversifies As A Major Catalyst ApproachesRhythm Pharmaceuticals Diversifies As A Major Catalyst Approaches
seekingalpha.com - April 9 at 4:02 PM
 Brokerages Set $31.25 Target Price for Rhythm Pharmaceuticals (RYTM) Brokerages Set $31.25 Target Price for Rhythm Pharmaceuticals (RYTM)
www.americanbankingnews.com - April 9 at 5:34 AM
BidaskClub Upgrades Rhythm Pharmaceuticals (RYTM) to HoldBidaskClub Upgrades Rhythm Pharmaceuticals (RYTM) to Hold
www.americanbankingnews.com - April 6 at 10:49 AM
Rhythm Pharmaceuticals Inc (RYTM) Expected to Post Earnings of -$0.44 Per ShareRhythm Pharmaceuticals Inc (RYTM) Expected to Post Earnings of -$0.44 Per Share
www.americanbankingnews.com - April 5 at 11:12 PM
Rhythm Pharmaceuticals (RYTM) Now Covered by Analysts at CowenRhythm Pharmaceuticals (RYTM) Now Covered by Analysts at Cowen
www.americanbankingnews.com - April 4 at 2:58 PM
Rhythm Pharmaceuticals (RYTM) Announces Licensing Agreement with Takeda for Development and Commercialization of Preclinical Treatment for PWSRhythm Pharmaceuticals (RYTM) Announces Licensing Agreement with Takeda for Development and Commercialization of Preclinical Treatment for PWS
www.streetinsider.com - April 2 at 4:05 PM
Rhythm Pharmaceuticals Announces Licensing Agreement with Takeda for the Development and Commercialization of Preclinical Treatment for Prader-Willi SyndromeRhythm Pharmaceuticals Announces Licensing Agreement with Takeda for the Development and Commercialization of Preclinical Treatment for Prader-Willi Syndrome
finance.yahoo.com - April 2 at 4:05 PM
Rhythm Pharmaceuticals (RYTM) Stock Rating Lowered by BidaskClubRhythm Pharmaceuticals (RYTM) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - March 28 at 9:16 PM
Rhythm Pharmaceuticals Incs Lock-Up Period To End  on April 3rd (NASDAQ:RYTM)Rhythm Pharmaceuticals Inc's Lock-Up Period To End on April 3rd (NASDAQ:RYTM)
www.americanbankingnews.com - March 27 at 1:02 AM
Rhythm Pharmaceuticals (RYTM) Upgraded to "Hold" by BidaskClubRhythm Pharmaceuticals (RYTM) Upgraded to "Hold" by BidaskClub
www.americanbankingnews.com - March 26 at 10:58 PM
D.C. drug company faces a new generics threatD.C. drug company faces a new generics threat
www.bizjournals.com - March 26 at 3:57 PM
 Rhythm Pharmaceuticals Inc (RYTM) Receives Consensus Recommendation of "Buy" from Brokerages Rhythm Pharmaceuticals Inc (RYTM) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 25 at 7:24 PM
Rhythm Pharmaceuticals Announces Presentation of Genetic Epidemiology of LEPR, POMC, And PCSK1 Variants at ENDO 2018Rhythm Pharmaceuticals Announces Presentation of Genetic Epidemiology of LEPR, POMC, And PCSK1 Variants at ENDO 2018
finance.yahoo.com - March 20 at 10:09 AM
Rhythm Pharmaceuticals (RYTM) Presents At 38th Annual Cowen and Company Healthcare Conference - SlideshowRhythm Pharmaceuticals (RYTM) Presents At 38th Annual Cowen and Company Healthcare Conference - Slideshow
seekingalpha.com - March 17 at 10:16 AM
Rhythm Pharmaceuticals (RYTM) Stock Rating Upgraded by BidaskClubRhythm Pharmaceuticals (RYTM) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 14 at 6:39 PM
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial ResultsRhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 12 at 4:58 PM
Diurnal Selects Worldwide Clinical Trials as Preferred CRO ProviderDiurnal Selects Worldwide Clinical Trials as Preferred CRO Provider
www.bizjournals.com - March 12 at 9:58 AM
Zacks: Rhythm Pharmaceuticals Inc (RYTM) Given $31.25 Consensus Target Price by BrokeragesZacks: Rhythm Pharmaceuticals Inc (RYTM) Given $31.25 Consensus Target Price by Brokerages
www.americanbankingnews.com - March 9 at 1:27 AM
Rhythm Pharmaceuticals to Present at Upcoming Investor Conferences in MarchRhythm Pharmaceuticals to Present at Upcoming Investor Conferences in March
finance.yahoo.com - March 7 at 4:44 PM
Rhythm Pharmaceuticals Inc (RYTM) Short Interest UpdateRhythm Pharmaceuticals Inc (RYTM) Short Interest Update
www.americanbankingnews.com - March 3 at 3:26 AM
Rhythm Pharmaceuticals Inc (RYTM) Expected to Announce Earnings of -$0.55 Per ShareRhythm Pharmaceuticals Inc (RYTM) Expected to Announce Earnings of -$0.55 Per Share
www.americanbankingnews.com - March 2 at 7:16 PM
Needham & Company LLC Reiterates "Buy" Rating for Rhythm Pharmaceuticals (RYTM)Needham & Company LLC Reiterates "Buy" Rating for Rhythm Pharmaceuticals (RYTM)
www.americanbankingnews.com - February 26 at 4:20 PM
Rhythm Pharmaceuticals (RYTM) Rating Lowered to Sell at BidaskClubRhythm Pharmaceuticals (RYTM) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - February 25 at 4:18 PM
Analysts Anticipate Rhythm Pharmaceuticals Inc (RYTM) to Announce ($0.55) Earnings Per ShareAnalysts Anticipate Rhythm Pharmaceuticals Inc (RYTM) to Announce ($0.55) Earnings Per Share
www.americanbankingnews.com - February 22 at 5:10 AM
 Rhythm Pharmaceuticals Inc (RYTM) Given $31.25 Consensus Price Target by Brokerages Rhythm Pharmaceuticals Inc (RYTM) Given $31.25 Consensus Price Target by Brokerages
www.americanbankingnews.com - February 18 at 5:24 AM
 Brokerages Anticipate Rhythm Pharmaceuticals Inc (RYTM) to Post -$0.55 EPS Brokerages Anticipate Rhythm Pharmaceuticals Inc (RYTM) to Post -$0.55 EPS
www.americanbankingnews.com - February 14 at 3:18 AM
Rhythm Pharmaceuticals (RYTM) Lowered to Hold at BidaskClubRhythm Pharmaceuticals (RYTM) Lowered to Hold at BidaskClub
www.americanbankingnews.com - February 4 at 6:22 AM
Zacks: Rhythm Pharmaceuticals Inc (RYTM) Receives Average Rating of "Buy" from AnalystsZacks: Rhythm Pharmaceuticals Inc (RYTM) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - February 2 at 7:22 PM
Rhythm Pharmaceuticals (RYTM) Rating Increased to Buy at BidaskClubRhythm Pharmaceuticals (RYTM) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - January 29 at 10:42 PM
Analysts Anticipate Rhythm Pharmaceuticals Inc (RYTM) to Post ($0.55) Earnings Per ShareAnalysts Anticipate Rhythm Pharmaceuticals Inc (RYTM) to Post ($0.55) Earnings Per Share
www.americanbankingnews.com - January 25 at 11:41 AM

SEC Filings

Rhythm Pharmaceuticals (NASDAQ:RYTM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Rhythm Pharmaceuticals (NASDAQ:RYTM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Rhythm Pharmaceuticals (NASDAQ RYTM) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.